MENU
+Compare
ASND
Stock ticker: NASDAQ
AS OF
Aug 25 closing price
Price
$190.37
Change
-$3.93 (-2.02%)
Capitalization
11.53B

ASND Ascendis Pharma A/S Forecast, Technical & Fundamental Analysis

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients... Show more

Industry: #Biotechnology
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ASND with price predictions
Aug 25, 2025

ASND in upward trend: price rose above 50-day moving average on July 31, 2025

ASND moved above its 50-day moving average on July 31, 2025 date and that indicates a change from a downward trend to an upward trend. In of 48 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for ASND crossed bullishly above the 50-day moving average on August 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ASND moved out of overbought territory on August 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where ASND's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ASND as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ASND turned negative on August 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ASND broke above its upper Bollinger Band on August 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ASND entered a downward trend on July 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.083). P/E Ratio (0.000) is within average values for comparable stocks, (54.504). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.646). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (19.685) is also within normal values, averaging (304.949).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ASND is expected to report earnings to fall 70.34% to -24 cents per share on November 13

Ascendis Pharma A/S ASND Stock Earnings Reports
Q3'25
Est.
$-0.24
Q2'25
Beat
by $0.45
Q1'25
Missed
by $0.11
Q4'24
Beat
by $0.34
Q3'24
Missed
by $0.18
The last earnings report on August 07 showed earnings per share of -81 cents, beating the estimate of -126 cents. With 354.30K shares outstanding, the current market capitalization sits at 11.53B.
A.I. Advisor
published General Information

General Information

a developer of drug candidates

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Tuborg Boulevard 12
Phone
+45 70222244
Employees
879
Web
https://www.ascendispharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MAKX50.721.64
+3.34%
ProShares S&P Kensho Smart Factories ETF
HIMU47.630.05
+0.11%
iShares High Yield Muni Active ETF
IBLC43.14-0.39
-0.90%
iShares Blockchain and Tech ETF
CHIQ23.15-0.26
-1.11%
Global X MSCI China Consumer Disc ETF
EXI168.78-1.95
-1.14%
iShares Global Industrials ETF

ASND and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
-2.02%
NUVL - ASND
38%
Loosely correlated
-2.67%
ORMP - ASND
37%
Loosely correlated
+1.40%
ZNTL - ASND
36%
Loosely correlated
-8.54%
AMRN - ASND
35%
Loosely correlated
-3.69%
AXON - ASND
34%
Loosely correlated
-0.35%
More